Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$102.81 USD
+0.42 (0.41%)
Updated May 24, 2024 04:00 PM ET
After-Market: $102.91 +0.10 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 501 - 508 ( 508 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2:EPS; Multiple Studies on Track for Initiation in 2015
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
FDA Accepts INDs for Lead Candidates BLU-285 and BLU-554; On Track to Begin Three Ph 1 Trials
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1:EPS; Looking to Mid:15 IND Submissions for Lead Product Candidates BLU-285 and BLU-554
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $41 Price Target; A Template for Targeted Therapies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D